Skip to main content
Premium Trial:

Request an Annual Quote

Merck Taps Nuevolution to Help Identify Drug Targets

NEW YORK (GenomeWeb News) – Nuevolution said today that it will use its DNA labeling platform to identify small-molecule leads against drug targets in a collaboration with Merck.
 
Copenhagen-based Nuevolution said it will use its Chemetics platform to screen multi-million member libraries for hit identification, and to perform hit-to-lead optimization.
 
Under the agreement, Merck will give Nuevolution an upfront payment, research funding, and milestone payments as candidate molecules move through preclinical and clinical development and onto the market.
 
Nuevolution also is eligible for royalties from sales of commercialized products resulting from the collaboration.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.